mercaptopurine / Generic mfg. - LARVOL DELTA

Medical Management of CD: Immunomodulators and Corticosteroids (IASGO 2026) - "Budesonide, with limitedsystemic exposure due to extensive first-pass metabolism, is effective for induction in mild-to-moderate CD limited to ileum and/or right colon. Systemic corticosteroids, such as oral prednisone orintravenous corticosteroids, rapidly induce remission in moderate-to-severe CD...Thiopurines, including azathioprine and 6-mercaptopurine, are not recommended for inductionbecause of their delayed onset of action (typically 8-12weeks) but may be used as steroid-sparingmaintenance therapy...Methotrexate (MTX) is another conventional immunomodulator. ParenteralMTX may be effective for induction and maintenance, particularly in steroid-dependent CD, whereaslow-dose oral MTX has not demonstrated consistent efficacy. Its use is limited by adverse effects,including hepatotoxicity and gastrointestinal intolerance, as well as teratogenicity, and it is generallyconsidered when other therapeutic options are unsuitable."

Immunomodulating • Crohn's disease • Gastroenterology • Genetic Disorders • Glaucoma • Hematological Malignancies • Immunology • Infectious Disease • Inflammatory Bowel Disease • Leukopenia • Lymphoma • Non-melanoma Skin Cancer • Ophthalmology • Pancreatitis • Skin Cancer • Solid Tumor • NUDT15

Characteristics and Outcomes of Central Nervous System Multiple Myeloma (IMS 2026) - "Pts received a median of 4 (R:1-16) doses of IT therapy, 4/5 received thiotepa (2 in combination with methotrexate & cytarabine, & mercaptopurine respectively), & 1 received methotrexate alone. Systemic treatment included combination of proteasome inhibitors, immunomodulatory drugs, anti-CD38 antibodies, selinexor, & other novel therapeutics (1 received ciltacabtagene autoleucel (ciltacel), & another received talquetamab followed by teclistamab)...Pts with CSF clearance (2/5) had received ciltacel & VD-PACE, while 2/5 with radiographic response had received ciltacel & daratumumab-pomalidomide... CNS myeloma pts had a dismal prognosis. All pts relapsed within 30m of ASCT, pointing to functionally high-risk disease. This highlights the need for increased awareness for early identification & CNS directed therapies."

CNS Disorders • Hematological Malignancies • Leukemia • Multiple Myeloma • Plasma Cell Leukemia

Safety of Inadvertent Live Vaccine Administration in Patients With Inflammatory Bowel Disease on Immune-Modifying Therapy (ACG 2026) - "The exposed cohort comprised IBD patients who received a live vaccine (measles, mumps, and rubella (MMR), varicella, measles, mumps, rubella, and varicella (MMRV)...Inclusion required a vaccine CPT code, â¥12 months of continuous enrollment prior to index date, an IBD diagnosis (â¥2 IBD-related outpatient visits), and a prescription for an immune-modifying therapy (anti-tumor necrosis factor (TNF), vedolizumab, ustekinumab, tofacitinib, upadacitinib, risankizumab, guselkumab, or mirikizumab) < 90 days of the index date...³Anti-TNF agents: infliximab, adalimumab, certolizumab, golimumab...6Immunomodulators: methotrexate, azathioprine, 6-mercaptopurine... 220 IBD patients met inclusion criteria for the live vaccine cohort (132 MMR, 73 varicella, 15 MMRV); 170 (77%) were on anti-TNF therapy and 30 (14%) on vedolizumab (Figure). The comparator group comprised 2,204 PCV13 recipients Table for baseline demographics. All-cause hospitalization or ED..."

Clinical • Gastroenterology • Gastrointestinal Disorder • Herpes Zoster • Immunology • Infectious Disease • Inflammation • Inflammatory Bowel Disease • Measles • Mumps • Pneumococcal Infections • Rubella • Varicella Zoster • IL23A

Risk of Incident Melanoma With TNF-Alpha Inhibitor Therapy in Inflammatory Bowel Disease: A Propensity-Matched Cohort Study (ACG 2026) - " Using the TriNetX U.S. Collaborative Network, we identified adults â¥18 years with IBD who initiated TNFi on or before February 7, 2024; controls initiated mesalamine or a non-TNFi biologic (ustekinumab, vedolizumab, risankizumab, mirikizumab, or guselkumab). Patients with prior melanoma or melanoma in situ; exposure to opposite-class advanced therapy, JAK inhibitors (tofacitinib, upadacitinib), thiopurines (azathioprine, mercaptopurine, thioguanine), or methotrexate before or within 5 years after index were excluded... In TNFi vs mesalamine, 21,848 matched pairs (mean age 38.9 ± 17.9 years; 51.1% female sex; 78.0% White) accrued mean follow-up of 2.5 years (median 3.0 years). There was no statistically significant difference in incident melanoma (0.10% vs 0.08%; OR 1.22, 95% CI 0.66â2.28; P=0.53) or composite outcome (0.11% each; OR 1.04, 0.59â1.82; P=0.89). Melanoma in situ alone was not separately reportable in this comparison due to small..."

Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Melanoma • Solid Tumor

Collateral Damage: IgA Nephropathy Complicating Long-Term Certolizumab Pegol Use in Crohn's Disease (ACG 2026) - "Case Description/ A 36-year-old male with CD diagnosed in 2010 (Paris classification: A2, L1, B2), underwent ileocolonic resection and was started on certolizumab pegol in 2011 after failing 5-aminosalicylic acid, 6-mercaptopurine, and infliximab therapy...Certolizumab pegol was stopped and CD treatment with vedolizumab was started. Treatment with corticosteroids, mycophenolate, losartan, and atrasentan was initiated...Targeted budesonide was not a treatment option in this case given prior bowel resection, which emphasizes a treatment consideration unique to CD patients. This case emphasizes the importance of routine renal monitoring in patients on long-term anti-TNF therapy. Figure: Light microscopy (PAS stain) demonstrating mesangial hypercellularity Figure: Immunofluorescence microscopy demonstrating diffuse mesangial IgA deposits"

Crohn's disease • Gastroenterology • Glomerulonephritis • IgA Nephropathy • Immunology • Inflammation • Inflammatory Bowel Disease • Nephrology • Renal Disease

Prevalence and Predictors of Fatigue in Inflammatory Bowel Disease: A Cross-Sectional Cohort Study With Subgroup Analysis of Quiescent Disease (ACG 2026) - "AZA, azathioprine; 6-MP, 6-mercaptopurine; CZP, certolizumab pegol; HBI, Harvey-Bradshaw Index; IFX, infliximab; PSQI, Pittsburgh Sleep Quality Index; RZB, risankizumab; TNF, tumour necrosis factor; TOFA, tofacitinib; UPA, upadacitinib; UST, ustekinumab; VDZ, vedolizumab. A total of 215 patients (71.2% Crohnâs, 42.3% female, median age 30) completed FACIT-F; 201 (93.5%) had classifiable IBD clinical activity (69 active, 132 quiescent) and included in the analysis. Moderate-severe fatigue affected 82 (38.1%) overall; 44.9% in active and 33.3% in quiescent disease (50% in those with elevated biomarkers) (Figure 1A). On univariate analysis, moderate-severe fatigue was associated with HBI (p=0.034), CRP (p=0.03), poor sleep (PSQIâ¥5; p< 0.001), depression (HADS-D â¥8; p< 0.001) and anxiety (HADS-A â¥8; p< 0.001) (Table 1)."

CNS Disorders • Crohn's disease • Depression • Fatigue • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Mood Disorders • CRP

Perioperative Safety Profile of IBD Medications: A Comparative Study of Real World Pharmacovigilance Data (ACG 2026) - "Golimumab showed elevated UC sepsis (1.88), whereas Adalimumab and Certolizumab showed lower CD sepsis (0.54, 0.27) and Adalimumab lower DVT and PE in both indications. Vedolizumab showed elevated UC DVT and PE (~1.5); natalizumab elevated CD PE (2.30); ustekinumab an isolated UC ileus signal (14.15)... Thiopurines and Methotrexate showed the most consistent signals across both indications: elevated ROR for sepsis (Azathioprine UC: ROR 2.03, CD: 1.85; Mercaptopurine UC: 2.64, CD: 2.04; Methotrexate UC: 1.57), DVT (Methotrexate UC 4.15, CD 2.33; Azathioprine CD 2.23, Mercaptopurine UC 2.29), and PE (Methotrexate UC 1.96; Azathioprine CD 1.84). Azathioprine UC also showed elevated anastomotic leak (7.15). Among anti-TNFs, infliximab showed elevated CD sepsis (2.12), DVT (1.90), and PE (1.82), as well as UC DVT (1.32)."

Adverse events • Clinical • Real-world • Real-world evidence • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Infectious Disease • Inflammation • Inflammatory Bowel Disease • Septic Shock • Ulcerative Colitis

Dual Biologic Therapy in a Pregnant Patient With Crohn's Disease and Axial Spondyloarthritis (ACG 2026) - "She had previous non-response to mesalamine, mercaptopurine, certolizumab pegol, adalimumab, infliximab, and upadacitinib, as well as combination therapy with upadacitinib and vedolizumab. She then achieved clinical remission with a combination of risankizumab and golimumab...Recent randomized trials showed improved rates of clinical remission in patients with ulcerative colitis and Crohnâs disease treated with dual therapy with guselkumab and golimumab compared to monotherapy...Data from the Pregnancy Inflammatory bowel disease And Neonatal Outcomes (PIANO) registry has shown no increased risk of pregnancy complications in patients treated with anti-TNF medications, immunomodulators, TNF/immunomodulator combination therapy, vedolizumab, and ustekinumab in patients with IBD. This case highlights emerging therapeutic strategies and the importance of patient centered multidisciplinary care for optimal pregnancy outcomes."

Clinical • Ankylosing Spondylitis • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Seronegative Spondyloarthropathies • Spondylarthritis • Ulcerative Colitis • CRP

Delayed Diagnosis of Crohnâs Disease Following Ileal Pouch-Anal Anastomosis: A Diagnostic Challenge (ACG 2026) - "Colonoscopy confirmed severe colitis, and he was started on 6-mercaptopurine with good response. In 2016, elevated liver enzymes and worsening psoriasis prompted transition to adalimumab, which was discontinued after suspected drug-induced lupus...With infliximab and methotrexate initiation, he achieved clinical and endoscopic quiescence...Post-operative diarrhea and bowel urgency were unresponsive to ciprofloxacin, loperamide, cholestyramine, and dicyclomine...He remains on vedolizumab for luminal disease and risankizumab for psoriasis with sustained remission...In our case, delayed recognition contributed to a complicated clinical course, including bacterial infection, pouch-related complications, and poorer quality of life. Hence, this case highlights the importance of maintaining diagnostic flexibility at the onset of suspected IBD and the need for prudent treatment reassessment in refractory or atypical disease courses."

Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Infectious Disease • Inflammation • Inflammatory Arthritis • Inflammatory Bowel Disease • Lupus • Psoriasis • Ulcerative Colitis

Herpes Zoster Infection as an Adverse Reaction to Treatments for Ulcerative Colitis: A Review of Reports to the FDA Adverse Events Reporting System (FAERS) (ACG 2026) - "Reports of ADRs of all FDA approved UC therapies including mesalamine, sulfasalazine, balsalazide, olsalazine, methotrexate, azathioprine, 6-mercaptopurine, infliximab, adalimumab, certolizumab, golimumab, vedolizumab, ustekinumab, mirikizumab, risankizumab, guselkumab, ozanimod, etrasimod, tofacitinib, and upadacitinib along with combination infliximab with methotrexate, infliximab with azathioprine, adalimumab with azathioprine, and golimumab with azathioprine were reviewed. Table 1 displays the total FAERS reports of ADRs and reported HZ infection in patients treated for UC. The JAK inhibitor tofacitinib showed increased risk of HZ with 58 total reports (ROR 2.79). In addition, methotrexate (ROR 1.83), azathioprine (ROR 1.74), 6-mercaptopurine (ROR 2.4), infliximab (ROR 2.49), and combination therapies of infliximab with methotrexate (ROR 2.61) and infliximab with azathioprine (ROR 2.91) demonstrated increased risk."

Adverse events • Review • Gastroenterology • Gastrointestinal Disorder • Herpes Zoster • Immunology • Infectious Disease • Inflammatory Bowel Disease • Ulcerative Colitis • Varicella Zoster • ROR1

Drug-Induced Pancreatitis Across UC Therapeutics: A Real-World Pharmacovigilance Study (ACG 2026) - " FAERS was queried for reports of pancreatitis associated with UC treatments including immunomodulators (azathioprine, mercaptopurine, methotrexate, tacrolimus), 5-aminosalicylates (mesalamine, balsalazide, olsalazine, sulfasalazine), anti-TNF agents (adalimumab, infliximab, golimumab, certolizumab pegol), integrin inhibitors (vedolizumab, natalizumab), IL-12/23 inhibitors (ustekinumab, risankizumab, guselkumab), JAK inhibitors (tofacitinib, upadacitinib), and S1P modulators (ozanimod, etrasimod). 83,046 reports with 612 pancreatitis cases were analyzed. Significantly elevated risk was observed with azathioprine (ROR 4.38, 95% CI 3.56-5.38), mesalamine (ROR 2.32, 95% CI 1.87-2.89), and infliximab (ROR 1.47, 95% CI 1.21-1.80; all p< 0.0001). Reduced risk was identified with adalimumab (ROR 0.60, 95% CI 0.49-0.74), vedolizumab (ROR 0.69, 95% CI 0.51-0.93), and ustekinumab (ROR 0.13, 95% CI 0.02-0.94)."

Adverse events • Clinical • Real-world • Real-world evidence • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Pancreatitis • Ulcerative Colitis • IL12A • ROR1

Arabic Translation and Validation of the IBD-Control Questionnaire in Patients With Inflammatory Bowel Disease (ACG 2026) - "Figure: IQR, interquartile range; CD, Crohnâs disease; UC, ulcerative colitis; HBI, Harvey-Bradshaw Index; CRP, C-reactive protein; FCP, fecal calprotectin; AZA, azathioprine; 6-MP, 6-mercaptopurine; CZP, certolizumab pegol; IFX, infliximab; VDZ, vedolizumab; UST, ustekinumab; RZB, risankizumab; TOFA, tofacitinib; UPA, upadacitinib; PSQI, Pittsburgh Sleep Quality Index; HADS, Hospital Anxiety and Depression Scale; FACIT-F, Functional Assessment of Chronic Illness TherapyâFatigue; VAS, visual analogue scale. A total of 203 patients completed the Arabic IBD-CQ (median age 31, 40.9% female, 70.0% CD) (Table 1) completed the Arabic IBD-CQ. The Arabic IBD-CQ demonstrated excellent internal consistency (Cronbach's α=0.820); all 8 items had corrected item-total râ¥0.44, and no item improved α if deleted. Construct validity was strong with expected-direction correlations: FACIT-F Ï=+0.61, HADS-Anxiety Ï=â0.53,..."

Clinical • CNS Disorders • Crohn's disease • Depression • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Mood Disorders • Ulcerative Colitis • CRP

The Emerging Role of Venetoclax in High-Risk Newly Diagnosed Patients With B-Cell Acute Lymphoblastic Leukemia (SOHO 2026) - "Patients were given 2 cycles of Hyper-CVAD for induction followed by high dose cytarabine (3 g twice a day for 3 days) and methotrexate (3 g/m2 on day 4) for 6 cycles as consolidation therapy; 6-mercaptopurine 100 mg/m2 daily, administered continuously. Venetoclax shows a synergistic effect with chemotherapy through elimination of malignant cells expressing BCL-2. The safety profile and the tolerance make it a good partner for high-dose chemotherapy in high-risk ALL patients. ALL: acute lymphoblastic leukemia, BCL-2: B-cell lymphoma 2, BID: twice daily, Hyper-CVAD: hyperfractionated cyclophosphamide, vincristine, doxorubicin (Adriamycin), dexamethasone."

Clinical • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • B Cell Lymphoma • Leukemia • Lymphoma • Oncology

Real-World Effectiveness of Biologics and Small Molecules in Steroid-Refractory Microscopic Colitis (ACG 2026) - "Patients with histologically confirmed microscopic colitis and prior exposure to budesonide or prednisone were included. Advanced therapies assessed included anti-TNF agents (infliximab, adalimumab), anti-integrin therapy (vedolizumab), interleukin inhibitors (ustekinumab, risankizumab), JAK inhibitors (tofacitinib, upadacitinib), and immunomodulators (azathioprine, 6-mercaptopurine, methotrexate)... 34 patients were included in this analysis. Average bowel movements significantly decreased from 9.1 ± 4.4 to 2.2 ± 2.1 per day following AT, corresponding to a mean reduction of 6.9 ± 3.9, demonstrating a clinical response (p< 0.001). Most patients demonstrated symptomatic improvement or resolution of diarrhea and over 50% reported improvement in urgency and abdominal pain."

Clinical • Real-world • Real-world effectiveness • Real-world evidence • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • CRP

Prevalence and Predictors of Poor Sleep Quality in Inflammatory Bowel Disease: A Cross-Sectional Cohort Study (ACG 2026) - "AZA, azathioprine; 6-MP, 6-mercaptopurine; CZP, certolizumab pegol; HBI, Harvey-Bradshaw Index; IFX, infliximab; PSQI, Pittsburgh Sleep Quality Index; RZB, risankizumab; TNF, tumour necrosis factor; TOFA, tofacitinib; UPA, upadacitinib; UST, ustekinumab; VDZ, vedolizumab. A total of 215 patients (71.2% Crohnâs, 42.3% female, median age 30) completed the PSQI. Of these patients, 201 (93.5%) had classifiable IBD activity (69 Active, 132 Quiescent) and were included in the analysis. Poor sleep was noted in 62.3%, depression (HADS-D ⥠8) in 30.7% and anxiety (HADS-A ⥠8) in 35.2% of the entire cohort."

CNS Disorders • Crohn's disease • Depression • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Mood Disorders • Sleep Disorder

Extranodal Rosai-Dorfman Disease Masquerading as Spinal Mass and Chronic Osteomyelitis: A Two-Case Series (SOHO 2026) - "Given progressive spinal and systemic disease, methotrexate and 6-mercaptopurine were initiated, with next-generation sequencing advised...Cladribine has shown activity in systemic disease, while MEK inhibition, particularly cobimetinib, has shown promising responses in patients with MAPK pathway alterations such as KRAS or MEK mutations... Extranodal RDD may present with misleading spinal or osseous lesions that mimic infection or malignancy, making histopathologic confirmation essential. Management should be individualized according to disease extent, symptoms, organ compromise, and molecular findings where available. BRAF V600E: B-Raf proto-oncogene, serine/threonine kinase valine to glutamic acid substitution at amino acid 600, CD: cluster of differentiation, HLA-B27: human leukocyte antigen B27, KRAS: Kirsten rat sarcoma viral oncogene homolog, MAPK: mitogenactivated protein kinase, MEK: mitogen-activated protein kinase kinase."

Clinical • Oncology • Solid Tumor • BRAF • CD1a • CD68 • KRAS • S100B

Age-Dependent Effects of GLP-1 Receptor Agonists on Clinical Outcomes in Inflammatory Bowel Disease: A Propensity-Matched Real-World Study (ACG 2026) - "Within each, GLP-1 RA users were propensity score matched 1:1 to non-users on gender; race/ethnicity (Hispanic, White, African-American, Asian, other); type 2 diabetes; Crohnâs disease; ulcerative colitis; hyperlipidemia; hypertension; ischemic heart disease; CKD; MASLD; obesity; insulin; SGLT2 inhibitors; prior hospitalization; and baseline IBD therapy including aminosalicylates (mesalamine, sulfasalazine), thiopurines/immunomodulators (azathioprine, mercaptopurine, methotrexate), anti-TNF agents (infliximab, adalimumab, certolizumab pegol, golimumab), vedolizumab, IL-12/23 and IL-23 inhibitors (ustekinumab, risankizumab), and JAK inhibitors (tofacitinib, upadacitinib). Primary cohorts (vs non-users): 1,958 (18â45), 5,412 (45â65), 2,928 ( >65). GLP-1 RA use was associated with lower hospitalization, ED visits, and IV corticosteroid use across all cohorts (Table 1, Figure 1). The 45â65 cohort had the most comprehensive benefit: reduced all-cause..."

Clinical • Clinical data • Real-world • Real-world evidence • Acute Kidney Injury • Cardiovascular • Chronic Kidney Disease • Coronary Artery Disease • Crohn's disease • Diabetes • Dyslipidemia • Gastroenterology • Gastrointestinal Disorder • Genetic Disorders • Heart Failure • Hypertension • Immunology • Inflammation • Inflammatory Bowel Disease • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease • Nephrology • Obesity • Pancreatitis • Renal Disease • Type 2 Diabetes Mellitus • Ulcerative Colitis • IL12A • IL23A

Beyond Immediate Release: FDM-Printed Pediatric 6-Mercaptopurine Chewable Tablets with Spontaneous In Situ Nanostructure Formation. (PubMed, AAPS PharmSciTech) - "Dynamic light scattering and transmission electron microscopy confirmed these findings. Overall, the developed platform demonstrates the potential of FDM-based structural engineering to produce personalized pediatric medicines and reveals that thermally processed polymeric matrices may function as dynamic drug delivery systems rather than conventional immediate-release dosage forms."

Journal • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Oncology • Pediatrics

Lead exposure decreases TPMT activity, highlighting the need for thiopurine dose adjustment in high-exposure individuals. (PubMed, J Trace Elem Med Biol) - "The observed inverse correlation between blood Pb2+ and TPMT levels emphasizes the clinical importance of individualizing thiopurine drug dosage, especially for patients exposed to high levels of Pb2+. In vitro studies involving site-directed mutagenesis and analysis of patients with Pb2+-binding site mutations will validate the precise Pb2+-binding sites involved in TPMT-inhibition."

Journal • Hematological Malignancies • Immunology • Leukemia • Oncology • TPMT

A Novel "Pediatric-Inspired" Regimen With Reduced Myelosuppressive Drugs for Adults (Aged 18-60) With Newly Diagnosed Ph Negative Acute Lymphoblastic Leukemia (clinicaltrials.gov) - P2 | N=39 | Active, not recruiting | Sponsor: Memorial Sloan Kettering Cancer Center | Trial completion date: Aug 2026 ➔ Aug 2027 | Trial primary completion date: Aug 2026 ➔ Aug 2027

Trial completion date • Trial primary completion date • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Oncology • Pediatrics

PACSIN2 regulates mercaptopurine cytotoxicity and cellular biomechanics through Rac1 modulation in intestinal epithelial cells. (PubMed, Front Pharmacol) - "Cytotoxicity was evaluated by MTT assay following exposure to MP and the Rac1 inhibitor NSC23766. These findings suggest that PACSIN2 modulates MP response by regulating Rac1 levels and cytoskeletal integrity, providing a molecular basis for the clinical association between PACSIN2 and thiopurine-related gastrointestinal toxicity. These insights may contribute to the development of personalized approaches to optimize thiopurine therapy in pediatric patients."

Journal • Acute Lymphocytic Leukemia • Gastroenterology • Gastrointestinal Disorder • Hematological Malignancies • Immunology • Inflammation • Inflammatory Bowel Disease • Leukemia • Oncology • Pediatrics • RAC1

Safety and Feasibility of a Mini-CVD/Methotrexate-Cytarabine Regimen With Induction Blinatumumab for Older and Frail Adults With Acute Lymphoblastic Leukemia: A Small Case Series From Brazil (SOHO 2026) - "Intervention: We report the first three cases treated with an approach similar to the MD Andersondesigned protocol for frail populations, with the omission of inotuzumab ozogamicin. Odd induction cycles consisted of the classic reduced-intensity CVD regimen, with rituximab 375 mg/m2 on day 1 for CD20-positive patients... Considering the challenges of treating older and frail adults with B-cell ALL, we demonstrated a promising approach with manageable toxicity that can be reproduced in private centers in Brazil and developing countries where blinatumomab is approved for first-line treatment. Additional data are needed to prove the efficacy of our approach. CD: cluster of differentiation, CNS: central nervous system, CVD: cyclophosphamide, vincristine, dexamethasone, MRD: minimal residual disease, Ph: Philadelphia chromosome, POMP: prednisone, vincristine (Oncovin), methotrexate, 6-mercaptopurine."

Clinical • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Oncology • CD20

Development of Inotuzumab Ozogamicin and Blinatumomab for Frontline Treatment of Older Patients with Ph-Negative B-Cell Acute Lymphoblastic Leukemia (SOHO 2024) - "In the single-arm, phase II INITIAL-1 trial (median age 64 years), the GMALL group administered 3 cycles of InO with dexamethasone as remission induction therapy, followed by reduced-intensity chemotherapy, and then maintenance therapy with mercaptopurine and methotrexate...With 15 months of follow-up, the estimated 1-year OS and leukemia-free survival rates were 73% and 65%, respectively.7 Similarly, MD Anderson studied a reduced-dose InO in combination with mini-hyperCVD (dose-reduced cyclophosphamide, vincristine, and dexamethasone, alternating with methotrexate and cytarabine) regimen in older patients (median age 68 years)...Elimination of conventional chemotherapy by using highly active targeted agents is highly effective in Ph-positive ALL, and the preliminary results for InO and blinatumomab with either dose-reduced or no conventional chemotherapy support some of these approaches as valid options for the treatment of older patients in clinical practice. Given..."

Clinical • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Oncology • CD19 • CD22

Hyper-CVAD and sequential blinatumomab for newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: a single-arm, single-centre, phase 2 trial. (PubMed, Lancet Haematol) - P2 | "Front-line sequential chemotherapy with blinatumomab resulted in encouraging long-term survival. Future randomised studies should evaluate the routine incorporation of blinatumomab in the treatment of patients with Ph-negative B-cell acute lymphocytic leukaemia."

Journal • P2 data • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Infectious Disease • Inflammation • Oncology • Respiratory Diseases • POMP

Unmasking a Hidden Burden: Chemotherapy-Induced and Exacerbated Diabetes in Paediatric Cancer: A Report of Two Cases. (PubMed, Niger Med J) - "A 4-year-old female with newly diagnosed Acute Lymphoblastic Leukaemia (ALL) was commenced on chemotherapy with prednisolone, 6-mercaptopurine, vincristine, doxorubicin, cyclophosphamide, L-asparaginase and cytarabine...An 11-year-old male was diagnosed with NHL, and chemotherapy was initiated with a regimen consisting of cyclophosphamide, vincristine, oral prednisolone, intrathecal methotrexate, and hydrocortisone...Treatment was commenced with metformin 500mg nocte. The FBG has normalized.These cases demonstrate that early detection of hyperglycaemia during childhood cancer chemotherapy is a low-cost, high-impact intervention that can prevent life-threatening complications such as DKA and its associated morbidity and mortality, especially in resource-constrained settings."

Journal • Acute Lymphocytic Leukemia • Cardiovascular • Diabetes • Hematological Malignancies • Hypertension • Hypoglycemia • Leukemia • Lymphoma • Metabolic Disorders • Obesity • Oncology • Pediatrics